Acs Medicinal Chemistry Letters
Overview
ACS Medicinal Chemistry Letters is a peer-reviewed scientific journal that publishes concise and impactful research in the field of medicinal chemistry. It focuses on the discovery and development of new therapeutic agents, including small molecules, peptides, and biologics. The journal provides a platform for rapid dissemination of innovative research, highlighting the latest advancements in drug design, synthesis, structure-activity relationships, and pharmacology.
Details
Details
Abbr.
ACS Med Chem Lett
Publisher
American Chemical Society
Start
2009
End
Continuing
Frequency
Monthly
e-ISSN
1948-5875
Country
United States
Language
English
Specialty
Chemistry
Metrics
Metrics
h-index / Ranks: 3937
86
SJR / Ranks: 4592
883
CiteScore / Ranks: 2600
7.40
JIF / Ranks: 2095
4.2
Recent Articles
1.
Zhao T, Liang S
ACS Med Chem Lett
. 2025 Feb;
16(2):178-179.
PMID: 39967651
The invention described in this patent application relates to oral compounds represented by Formula I. These compounds are designed to specifically target and inhibit KRAS alleles, providing both therapeutic and...
2.
3.
Rooney T, Aldred G, Winpenny D, Scott H, Willems H, Voytyuk I, et al.
ACS Med Chem Lett
. 2025 Feb;
16(2):327-335.
PMID: 39967649
The protein kinase NUAK1 has been implicated in various biological functions including cell adhesion, migration and proliferation. Genetic reduction of NUAK1 expression has notably been shown to lower total levels...
4.
Lucarini E, DAntongiovanni V, Antonioli L, Ghelardini C, Di Cesare Mannelli L, Ferraroni M, et al.
ACS Med Chem Lett
. 2025 Feb;
16(2):347.
PMID: 39967648
[This corrects the article DOI: 10.1021/acsmedchemlett.4c00284.].
5.
Kargbo R
ACS Med Chem Lett
. 2025 Feb;
16(2):222-223.
PMID: 39967647
The development of targeted protein degraders offers novel strategies for treating cancer and chronic viral infections. This Patent Highlight integrates bifunctional degraders, leveraging autophagy via p62, and substituted oxazolone compounds...
6.
Takano R, Ohoka N, Kurohara T, Arakawa N, Ohgane K, Inoue T, et al.
ACS Med Chem Lett
. 2025 Feb;
16(2):258-262.
PMID: 39967646
New ubiquitin ligase (E3) ligands are crucial for developing proteolysis-targeting chimeras (PROTACs) to induce the degradation of a target protein. In this study, we developed a PROTAC using the antipsychotic...
7.
Soares P, Rahaman M, Maher P, Silverman R
ACS Med Chem Lett
. 2025 Feb;
16(2):294-300.
PMID: 39967645
Alzheimer's disease (AD) incurs heavy costs for both the population and health systems. Nevertheless, the drugs available only provide minimal symptomatic management without much impact on the patients' quality of...
8.
Sabnis R
ACS Med Chem Lett
. 2025 Feb;
16(2):194-195.
PMID: 39967644
Provided herein are novel 6-substituted-3-phenylisoindolin-1-ones as Cbl-b inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
9.
Abdel-Magid A
ACS Med Chem Lett
. 2025 Feb;
16(2):204-206.
PMID: 39967643
The invention in this patent application relates to 2-amino-[1,2,4]triazolo[1,5-]pyridin derivatives represented generally herein as formula 1. These compounds have activities as receptor-interacting protein kinase 1 (RIPK1) inhibitors and may potentially...
10.
Leveille A, Schwarzrock T, Brown H, True B, Plasencia J, Neudecker P, et al.
ACS Med Chem Lett
. 2025 Feb;
16(2):271-277.
PMID: 39967642
We report the first structure-activity studies of arylidene-indolinone compound , which was reported as a ligand of autophagy-related protein LC3B. The literature has conflicting information on the binding affinity of...